Bonus Biogroup (Uplisting)

Print
General Information
Business:

Note: This is NOT an IPO. This is an uplisting to the NASDAQ from the Tel Aviv Stock Exchange (TASE). This uplisting – a public offering – will consist of American Depositary Shares (ADS).

(Incorporated in Israel)

We are a clinical-stage biotechnology company focused on developing next-generation therapies. Our mission is to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products that address severe conditions with limited treatment options. By leveraging our deep expertise and advancements in tissue engineering and cell therapy, we are developing BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage, both of which, we believe, may address significant unmet clinical and market needs.

Cell and cell-based therapies, in which therapeutic cells are combined with other modalities, such as scaffolds for tissue engineering, are categorized based on the cells’ origin. Autologous (or self-derived) treatments utilize the patient’s own cells, whereas allogeneic treatments employ cells from external healthy human donors. While autologous cell therapies, especially those harnessing the patient’s immune cells, are predominantly utilized in cancer treatment (immunotherapy), autologous, non-immune cell therapies, mostly involving mesenchymal stomal cells (MSC) and induced pluripotent stem cells, are under extensive investigation for their potential to repair damaged tissue such as bone, cartilage, heart muscle, and more. Within this field of autologous, non-immune cell therapies, our primary focus is on bone regeneration, with the potential to expand in the future to broader applications of MSC-based tissue engineering. Allogeneic cell therapies, particularly those involving MSCs, are being explored for treating various diseases characterized by excessive immune system activity. This is also an area of focus for us.

 

Our research and development efforts within this cell and cell-based therapy space have yielded our two leading product candidates:

 

● BonoFill is a personalized, tissue-engineered, potentially injectable live-human bone graft derived from the patient cells for bone tissue regeneration, which exemplifies the application of autologous cells. BonoFill is designed to address the limitations of existing bone regeneration and reconstruction therapies. This innovative cell-based product candidate combines cells on a three-dimensional (3D) biocompatible and bioactive mineral scaffold cultivated using our proprietary bioreactor growth system. The result is a live bone graft grown ex vivo (outside the human body), which is intended to be tailored to each patient’s unique biological, physical, and clinical needs. The manufacturing process of BonoFill takes approximately two weeks from receiving the patient cell sample. By leveraging the natural compatibility of autologous cells with the patient’s body, BonoFill aims to optimize treatment outcomes, minimize immune reactions, and eliminate the risk of graft failure; and

 

 

● MesenCure, an enhanced investigational allogeneic cell therapy designed for treating inflammation and tissue damage, is initially seeking indication as an adjunct therapy to standard of care for treating respiratory distress, including Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition caused by the lungs’ inability to adequately oxygenate the body. The active pharmaceutical ingredient in MesenCure is an innovative composition of allogeneic cells derived from healthy donor adipose tissue MSCs through a proprietary process designed to enhance the MSCs’ therapeutic potential. Currently in development to be administered in up to three doses, these cells are designed to target the lungs, presumably leveraging multiple pleiotropic mechanisms to counteract inflammation and foster lung tissue regeneration, with the potential to address the multifaceted pathology of acute lung injury (ALI) and subsequent respiratory distress.

 

 

1

 

 

Our Pipeline

 

The following table summarizes our clinical development pipeline, detailing each investigational product candidate along with its respective application and latest stage of development:

 

 

Product Candidate Indication(s) / Condition(s) Preclinical Phase I/II Phase III
BonoFill Maxillofacial bone defects in the upper and lower jaw bones Completed ●   Completed Phase II in 2024 for sinus augmentation and void filling ●    Initiation is planned for 2026
Defects in long and short limb bones incapable of self-healing or untreatable by standard techniques Completed ●   Phase II ongoing; completion of enrollment expected in 2026

 

●   Phase II interim results expected in 2026; final results expected in 2027

 

 ●    Initiation is planned for 2028
MesenCure Respiratory distress Completed ●   Completed Phase II in 2022 for treating pulmonary manifestations of COVID in severely ill patients ●   IND clearance for a Phase III study in respiratory distress related to COVID-19 granted by the FDA in February 2025. Initiation of study in all-cause respiratory distress is planned for 2026

 

 

 

Note: Net loss is in U.S. dollars (converted from Israeli shekels) for the 12 months that ended June 30, 2025. Bonus BioGroup has not produced any revenue, according to the prospectus.

 

 

 

 
Industry: Bone implant
Employees: 49
Founded: 1981
Contact Information
Address Haifa, Israel
Phone Number
Web Address http://www.bonus-bio.com/
View Prospectus: Bonus Biogroup (Uplisting)
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-8.12 mil (last 12 months)
IPO Profile
Symbol BONS
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $10.0 mil
Manager / Joint Managers Titan Partners Group (A Division of American Capital Partners)
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change